Northwest Biotherapeutics Inc. has announced the cancellation of 17% of the challenged 2020 option awards to company management and directors as part of a settlement agreement related to litigation in the Delaware Court of Chancery. Under the terms of the settlement, the company’s insurance carriers will pay $2.25 million to the company, and all claims between the parties will be fully resolved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-004146), on January 15, 2026, and is solely responsible for the information contained therein.